Novo Nordisk to seek regulatory approval for CagriSema obesity drug early 2026
Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its previous expectation to file towards end-2025.
The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...
A commission proposed a new definition of obesity focused on how excess fat affects the body, rather than assessing body mass ...
Comprehensive study exposes critical health risks of obesity, including diabetes, heart disease, and cancer, while offering ...
Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...
The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...
GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
Major heart health risk factors like obesity, diabetes and high blood pressure remain on the rise in the United States, ...
Obesity is the mother of many non-communicable diseases, and that is why it has to be taken seriously," Dr. Naval Kishore ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback